- Home
- COCP vs SYBX Comparison
COCP vs SYBX Comparison
Compare COCP & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- SYBX
- Stock Information
- Founded
- COCP N/A
- SYBX N/A
- Country
- COCP United States
- SYBX United States
- Employees
- COCP N/A
- SYBX 6
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- COCP Health Care
- SYBX Health Care
- Exchange
- COCP Nasdaq
- SYBX Nasdaq
- Market Cap
- COCP 18.3M
- SYBX 15.9M
- IPO Year
- COCP N/A
- SYBX N/A
- Fundamental
- Price
- COCP $2.15
- SYBX $1.36
- Analyst Decision
- COCP Strong Buy
- SYBX Buy
- Analyst Count
- COCP 1
- SYBX 4
- Target Price
- COCP $7.00
- SYBX $15.50
- AVG Volume (30 Days)
- COCP 22.2K
- SYBX 11.7K
- Earning Date
- COCP 11-13-2024
- SYBX 11-12-2024
- Dividend Yield
- COCP N/A
- SYBX N/A
- EPS Growth
- COCP N/A
- SYBX N/A
- EPS
- COCP N/A
- SYBX N/A
- Revenue
- COCP N/A
- SYBX $2,777,000.00
- Revenue This Year
- COCP N/A
- SYBX N/A
- Revenue Next Year
- COCP N/A
- SYBX N/A
- P/E Ratio
- COCP N/A
- SYBX N/A
- Revenue Growth
- COCP N/A
- SYBX 292.23
- 52 Week Low
- COCP $1.33
- SYBX $1.22
- 52 Week High
- COCP $3.10
- SYBX $5.12
- Technical
- Relative Strength Index (RSI)
- COCP 64.04
- SYBX 40.49
- Support Level
- COCP $1.65
- SYBX $1.37
- Resistance Level
- COCP $1.82
- SYBX $1.58
- Average True Range (ATR)
- COCP 0.17
- SYBX 0.09
- MACD
- COCP 0.03
- SYBX -0.00
- Stochastic Oscillator
- COCP 64.10
- SYBX 0.00
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.